Evolution of the Randomized Clinical Trial in the Era of Precision Oncology

Analysis of 298 RCTs in breast, colorectal, and NSCLC published 2010-2020 found the most common primary endpoint is now progression-free survival (surrogate endpoint), the majority (89%) are funded by industry, and use of a professional medical writer is increasing.

Source:

JAMA Oncology